AKESO INC. O.N. (4RY) - Total Liabilities
Based on the latest financial reports, AKESO INC. O.N. (4RY) has total liabilities worth €7.05 Billion EUR (≈ $8.25 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 4RY asset resilience ratio to evaluate the company's liquid asset resilience ratio.
AKESO INC. O.N. - Total Liabilities Trend (2021–2025)
This chart illustrates how AKESO INC. O.N.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see AKESO INC. O.N. (4RY) total assets.
AKESO INC. O.N. Competitors by Total Liabilities
The table below lists competitors of AKESO INC. O.N. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SGH Ltd
AU:SGH
|
Australia | AU$7.81 Billion |
|
UMB Financial Corporation
NASDAQ:UMBF
|
USA | $64.22 Billion |
|
Akzo Nobel NV
AS:AKZA
|
Netherlands | €9.13 Billion |
|
Harmony Gold Mining Co. Ltd.
JSE:HAR
|
South Africa | ZAC62.42 Billion |
|
BAWAG Group AG
VI:BG
|
Austria | €68.05 Billion |
|
FSN E-Commerce Ventures Limited
NSE:NYKAA
|
India | Rs31.09 Billion |
|
Nordex SE
F:NDX1
|
Germany | €5.47 Billion |
|
Futu Holdings Ltd
NASDAQ:FUTU
|
USA | $204.83 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down AKESO INC. O.N.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See AKESO INC. O.N. (4RY) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AKESO INC. O.N.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AKESO INC. O.N. (2021–2025)
The table below shows the annual total liabilities of AKESO INC. O.N. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €7.05 Billion ≈ $8.25 Billion |
+17.55% |
| 2024-12-31 | €6.00 Billion ≈ $7.02 Billion |
+28.72% |
| 2023-12-31 | €4.66 Billion ≈ $5.45 Billion |
+58.16% |
| 2022-12-31 | €2.95 Billion ≈ $3.45 Billion |
+93.24% |
| 2021-12-31 | €1.53 Billion ≈ $1.78 Billion |
-- |
About AKESO INC. O.N.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell car… Read more